Brokerages Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Price Target at $690.00

Quince Therapeutics, Inc. (NASDAQ:QNCX) has been assigned a consensus rating of “Hold” from the ten brokerages that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $690.00.

A number of analysts have weighed in on the company. Weiss Ratings cut Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Zacks Research raised Quince Therapeutics to a “hold” rating in a report on Wednesday, June 24th. Cantor Fitzgerald assumed coverage on Quince Therapeutics in a research note on Tuesday, June 23rd. They set an “overweight” rating and a $80.00 price target for the company. Lifesci Capital raised Quince Therapeutics to a “strong-buy” rating in a report on Monday, June 29th. Finally, Wall Street Zen raised Quince Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 17th.

Institutional Investors Weigh In On Quince Therapeutics

Hedge funds have recently modified their holdings of the company. Bridgeway Capital Management LLC grew its position in shares of Quince Therapeutics by 20.9% in the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after purchasing an additional 22,200 shares during the period. XTX Topco Ltd purchased a new position in Quince Therapeutics during the second quarter worth about $37,000. Intellectus Partners LLC purchased a new position in Quince Therapeutics during the fourth quarter worth about $179,000. Hudson Bay Capital Management LP acquired a new stake in Quince Therapeutics in the 4th quarter worth about $213,000. Finally, Renaissance Technologies LLC boosted its stake in Quince Therapeutics by 14.8% in the 4th quarter. Renaissance Technologies LLC now owns 538,100 shares of the company’s stock worth $1,803,000 after buying an additional 69,502 shares during the last quarter. 30.75% of the stock is owned by institutional investors and hedge funds.

Quince Therapeutics Stock Performance

Shares of Quince Therapeutics stock opened at $17.54 on Monday. The business has a 50-day simple moving average of $20.66 and a 200-day simple moving average of $146.06. Quince Therapeutics has a one year low of $15.10 and a one year high of $909.98. The company has a market cap of $17.19 million, a PE ratio of -0.08 and a beta of 1.40.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($26.00) by $25.41. On average, sell-side analysts predict that Quince Therapeutics will post -0.96 earnings per share for the current fiscal year.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.